FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285228312> ?p ?o ?g. }

• W4285228312 endingPage "175883592211050" @default.
• W4285228312 startingPage "175883592211050" @default.
• W4285228312 abstract "Combinatorial inhibition of epidermal growth factor receptor (EGFR) and BRAF shows remarkable clinical benefits in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). However, the tumor may inevitably develop resistance to the targeted therapy, thereby limiting the response rate and durability. This study aimed to determine the genetic alterations associated with intrinsic and acquired resistance to EGFR/BRAF inhibitors in BRAF V600E-mutant mCRC.Targeted sequencing of 520 cancer-related genes was performed in tumor tissues and in plasma samples collected from patients with BRAF V600E-mutant mCRC, who were treated with EGFR/BRAF ± MEK inhibitors, before and after the targeted treatment. Clinical benefit was defined as an objective response or a stable disease lasting longer than the median progression-free survival (PFS).In all, 25 patients with BRAF V600E-mutant mCRC were included in this study. Those with RNF43 mutations (n = 8) were more likely to achieve clinical benefit from EGFR/BRAF inhibitors than those with wild-type RNF43 (87.5% versus 37.5%, p = 0.034). Genetic alterations in receptor tyrosine kinase genes (n = 6) were associated with worse PFS (p = 0.005). Among the 23 patients whose disease progressed after the EGFR/BRAF-targeted therapy, at least one acquired resistance-related mutation was detected in 12 patients. Acquired mutations were most frequently observed in the mitogen-activated protein kinase pathway-related genes (n = 9), including KRAS (G12D and Q61H/R), NRAS (Q61L/R/K and amplification), BRAF (amplification), and MEK1 (K57T). MET amplification and PIK3R1 Q579fs mutation emerged in three patients and one patient, respectively, after disease progression.Multiple genetic alterations are associated with clinical benefits and resistance to EGFR/BRAF inhibitors in BRAF V600E-mutant mCRC. Our findings provide novel insights into strategies for overcoming resistance to EGFR/BRAF inhibitors in patients with BRAF V600E-mutant mCRC." @default.
• W4285228312 created "2022-07-14" @default.
• W4285228312 creator A5003866201 @default.
• W4285228312 creator A5004181171 @default.
• W4285228312 creator A5006012404 @default.
• W4285228312 creator A5006706475 @default.
• W4285228312 creator A5040697321 @default.
• W4285228312 creator A5043941211 @default.
• W4285228312 creator A5052883326 @default.
• W4285228312 creator A5065755796 @default.
• W4285228312 creator A5072537482 @default.
• W4285228312 creator A5081207491 @default.
• W4285228312 date "2022-01-01" @default.
• W4285228312 modified "2023-10-18" @default.
• W4285228312 title "Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors" @default.
• W4285228312 cites W1542666708 @default.
• W4285228312 cites W1922733886 @default.
• W4285228312 cites W2007513598 @default.
• W4285228312 cites W2049171090 @default.
• W4285228312 cites W2058142370 @default.
• W4285228312 cites W2062069596 @default.
• W4285228312 cites W2110682589 @default.
• W4285228312 cites W2112180493 @default.
• W4285228312 cites W2121260558 @default.
• W4285228312 cites W2133523341 @default.
• W4285228312 cites W2136799264 @default.
• W4285228312 cites W2146737519 @default.
• W4285228312 cites W2262414037 @default.
• W4285228312 cites W2420593137 @default.
• W4285228312 cites W2471247568 @default.
• W4285228312 cites W2472184398 @default.
• W4285228312 cites W2561667833 @default.
• W4285228312 cites W2598954950 @default.
• W4285228312 cites W2731836567 @default.
• W4285228312 cites W2736345028 @default.
• W4285228312 cites W2760461398 @default.
• W4285228312 cites W2791335314 @default.
• W4285228312 cites W2791410762 @default.
• W4285228312 cites W2969491369 @default.
• W4285228312 cites W2977895282 @default.
• W4285228312 cites W3005829120 @default.
• W4285228312 cites W3022030942 @default.
• W4285228312 cites W3029660293 @default.
• W4285228312 cites W3092809369 @default.
• W4285228312 cites W3094213747 @default.
• W4285228312 cites W3100313727 @default.
• W4285228312 cites W3116507528 @default.
• W4285228312 cites W3123642801 @default.
• W4285228312 cites W3128646645 @default.
• W4285228312 cites W3164609895 @default.
• W4285228312 cites W3171530808 @default.
• W4285228312 doi "https://doi.org/10.1177/17588359221105022" @default.
• W4285228312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35747165" @default.
• W4285228312 hasPublicationYear "2022" @default.
• W4285228312 type Work @default.
• W4285228312 citedByCount "7" @default.
• W4285228312 countsByYear W42852283122023 @default.
• W4285228312 crossrefType "journal-article" @default.
• W4285228312 hasAuthorship W4285228312A5003866201 @default.
• W4285228312 hasAuthorship W4285228312A5004181171 @default.
• W4285228312 hasAuthorship W4285228312A5006012404 @default.
• W4285228312 hasAuthorship W4285228312A5006706475 @default.
• W4285228312 hasAuthorship W4285228312A5040697321 @default.
• W4285228312 hasAuthorship W4285228312A5043941211 @default.
• W4285228312 hasAuthorship W4285228312A5052883326 @default.
• W4285228312 hasAuthorship W4285228312A5065755796 @default.
• W4285228312 hasAuthorship W4285228312A5072537482 @default.
• W4285228312 hasAuthorship W4285228312A5081207491 @default.
• W4285228312 hasBestOaLocation W42852283121 @default.
• W4285228312 hasConcept C104317684 @default.
• W4285228312 hasConcept C121608353 @default.
• W4285228312 hasConcept C126322002 @default.
• W4285228312 hasConcept C143065580 @default.
• W4285228312 hasConcept C143998085 @default.
• W4285228312 hasConcept C184235292 @default.
• W4285228312 hasConcept C21790070 @default.
• W4285228312 hasConcept C2776470698 @default.
• W4285228312 hasConcept C2777506169 @default.
• W4285228312 hasConcept C2779438470 @default.
• W4285228312 hasConcept C2781187634 @default.
• W4285228312 hasConcept C2781230642 @default.
• W4285228312 hasConcept C2781249067 @default.
• W4285228312 hasConcept C501734568 @default.
• W4285228312 hasConcept C502942594 @default.
• W4285228312 hasConcept C526805850 @default.
• W4285228312 hasConcept C54355233 @default.
• W4285228312 hasConcept C57074206 @default.
• W4285228312 hasConcept C71924100 @default.
• W4285228312 hasConcept C86803240 @default.
• W4285228312 hasConceptScore W4285228312C104317684 @default.
• W4285228312 hasConceptScore W4285228312C121608353 @default.
• W4285228312 hasConceptScore W4285228312C126322002 @default.
• W4285228312 hasConceptScore W4285228312C143065580 @default.
• W4285228312 hasConceptScore W4285228312C143998085 @default.
• W4285228312 hasConceptScore W4285228312C184235292 @default.
• W4285228312 hasConceptScore W4285228312C21790070 @default.
• W4285228312 hasConceptScore W4285228312C2776470698 @default.
• W4285228312 hasConceptScore W4285228312C2777506169 @default.

• next